Atherosclerosis is a disease of the artery walls in which fatty deposits, immune cells, and scar tissue build up into plaques that narrow blood vessels and restrict blood flow. Vascular calcification, the hardening of those plaques (or the artery wall itself) with calcium-phosphate mineral, is not a separate disease but a process deeply woven into atherosclerosis at nearly every stage. The relationship between the two is more complicated than “hardened arteries are worse arteries,” though. The size, location, and pattern of calcification within a plaque can either destabilize it toward rupture or lock it into a more stable, less dangerous form.
How Atherosclerosis Begins
The process starts with damage to the thin inner lining of an artery, the endothelium. High blood pressure, smoking, elevated blood sugar, and other stressors make this lining more permeable than it should be. Low-density lipoprotein (LDL) cholesterol particles slip through the damaged lining and become trapped in the artery wall, where they undergo chemical modification by oxidation. These oxidized LDL particles are toxic to the surrounding tissue and trigger an alarm that recruits immune cells from the bloodstream.
White blood cells called monocytes arrive and mature into macrophages, whose job is to engulf the oxidized LDL and clean it up. But the process goes wrong: the macrophages gorge on so much oxidized fat that they become bloated “foam cells,” unable to leave the artery wall. This accumulation of foam cells forms what pathologists call a fatty streak, the earliest visible sign of atherosclerosis. Over time, smooth muscle cells migrate in from deeper layers of the artery wall, a fibrous cap forms over the growing mass, and a full-fledged plaque takes shape.1PubMed Central. Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis2PubMed Central. Modification macrophage to foam cells in atherosclerosis disease: some factors stimulate or inhibit this process
When Arteries Start to Calcify
Calcification is not just calcium passively collecting in damaged tissue. It is an active, cell-driven process that resembles bone formation in some unsettling ways. The key players are vascular smooth muscle cells, which normally sit in the artery wall and contract to regulate blood pressure. Under the chronic stress of atherosclerosis, these cells can switch their identity. Instead of behaving like muscle, they begin expressing proteins normally found in bone-building cells. Researchers have identified a whole menu of alternate identities these cells can adopt, including osteogenic (bone-like), foam-cell-like, and inflammatory forms.3Cell Death Discovery. Vascular smooth muscle cell metabolic reprogramming and phenotypic remodeling in atherosclerosis
The osteogenic switch is the one that matters most for calcification. When smooth muscle cells adopt this bone-like identity, they start depositing calcium-phosphate mineral, essentially building tiny bone structures inside the artery wall. A signaling protein called TGF-β1 is one key driver of this transformation, and experiments have shown that blocking certain upstream signals can reduce both the identity switch and the mineral deposition that follows.4PubMed Central. MFG-E8 promotes osteogenic transdifferentiation of smooth muscle cells and vascular calcification by regulating TGF-β1 signaling High phosphate levels and a transcription factor called RUNX2 also play central roles; when researchers knocked out RUNX2 specifically in smooth muscle cells, calcification driven by oxidative stress was significantly reduced.5PubMed Central. Key regulators of vascular calcification in chronic kidney disease: Hyperphosphatemia, BMP2, and RUNX26PubMed Central. Smooth Muscle Cell-Specific Runx2 Deficiency Inhibits Vascular Calcification
Two Different Kinds of Calcification
Not all vascular calcification is the same, and the distinction matters for what happens to you. Calcium can deposit in two different layers of the artery wall, and each pattern leads to different problems.
Intimal calcification occurs within atherosclerotic plaques themselves, in the inner layer of the artery, typically near lipid and cholesterol deposits. This is the kind most closely linked to plaque rupture and heart attacks. Medial calcification, sometimes called Mönckeberg-type, occurs in the middle muscular layer of the artery wall independently of cholesterol plaques. It tends to stiffen arteries without necessarily narrowing them and is especially common in people with kidney disease and diabetes. The two patterns can also favor different kinds of arteries: large elastic arteries like the aorta versus smaller muscular arteries further from the heart. Clinical studies have confirmed that distinguishing between the two is clinically relevant because each type carries different consequences for treatment and prognosis.7Clinical Journal of the American Society of Nephrology. Media Calcification and Intima Calcification Are Distinct Entities in Chronic Kidney Disease
The Calcification Paradox and Plaque Stability
Here is where the picture gets counterintuitive. You might assume that more calcium in an artery is always bad, but the reality depends heavily on the size and pattern of the deposits.
Tiny calcium specks, called microcalcifications or “spotty” calcification, embedded in a plaque’s fibrous cap are genuinely dangerous. They create a mismatch in stiffness between the rigid calcium deposit and the surrounding soft tissue, concentrating mechanical stress at the boundary. One computational study found that closely spaced microcalcifications could increase local tissue stress by roughly fivefold, and that the stress in the thinnest intact caps without microcalcifications was far below the estimated threshold for rupture.8PubMed Central. A mechanistic analysis of the role of microcalcifications in atherosclerotic plaque stability: potential implications for plaque rupture Experimental work using tissue-engineered plaque models has further supported the idea that microcalcification clusters in caps can increase rupture risk and even shift where the rupture occurs.9PubMed. The effect of presence and location of microcalcifications on atherosclerotic plaque rupture: A tissue-engineering approach
Large, dense sheets of calcium, called macrocalcification, tell a different story. These bulky deposits are generally considered a stabilizing factor. They act almost like internal armor, stiffening the plaque so that it resists the mechanical forces that would otherwise tear it apart. An optical coherence tomography study of coronary arteries confirmed that macrocalcification was associated with more stable plaque features, while spotty calcification was linked to instability.10PubMed Central. Coronary artery calcification and plaque stability: an optical coherence tomography study So the same mineral can be protective or harmful depending on how much of it there is and exactly where it sits.
How Inflammation Fuels Calcification
Chronic inflammation is the engine behind much of vascular calcification, and it connects the disease back to the immune response that started the whole process. Inflammatory signaling molecules, particularly members of the interleukin family like IL-1β, IL-6, and IL-17A, push smooth muscle cells toward their osteogenic identity by activating pathways that ramp up the expression of bone-forming proteins.11PubMed Central. Interleukin family in vascular calcification: molecular mechanisms and therapeutic perspectives TNF-α, another inflammatory signal, has been shown to enhance the osteogenic switch in the presence of elevated phosphate, driving up the expression of bone-related genes in smooth muscle cells.12Nephrology Dialysis Transplantation. New insights into the key role of interleukin 6 in vascular calcification of chronic kidney disease
This creates a vicious cycle. The dying foam cells and debris inside a plaque release signals that recruit more immune cells. Those immune cells secrete inflammatory molecules that push smooth muscle cells to calcify. The calcification process itself, especially the microcalcification phase, generates further inflammation. Breaking this cycle is one of the central challenges in treating atherosclerotic cardiovascular disease.
The Body’s Natural Defenses Against Calcification
If inflammation and metabolic stress are constantly pushing arteries to calcify, why doesn’t every adult have rock-hard arteries? Because the body maintains a set of anti-calcification defenses that usually keep the process in check. Extracellular fluids contain several molecules that actively prevent calcium-phosphate crystals from forming. Matrix Gla protein (MGP) is one of the most important: it requires vitamin K to become activated, and once activated, it binds calcium and keeps it from precipitating in soft tissues. Fetuin-A, a protein produced by the liver, performs a similar scavenging role. Osteopontin, another inhibitor, blocks crystal growth. Pyrophosphate, a small molecule, directly prevents hydroxyapatite crystals from forming; when pyrophosphate levels fall, calcification accelerates.13Atherosclerosis. New insights into endogenous mechanisms of protection against arterial calcification
Vascular calcification essentially represents a failure of these defense systems, whether because the pro-calcification signals become too strong, the inhibitors become depleted or disabled, or both. This framing matters because several of the most promising therapeutic strategies aim to restore or boost these natural inhibitors rather than trying to dissolve existing calcium.
Metabolic Conditions That Accelerate Calcification
Two conditions stand out as especially powerful accelerators of vascular calcification: chronic kidney disease and diabetes.
When kidneys fail, they lose the ability to excrete phosphate efficiently, and blood phosphate levels rise. This hyperphosphatemia is a direct stimulus for vascular calcification, and observational studies have consistently identified it as a cardiovascular risk factor in people with kidney disease.14PubMed Central. Hyperphosphatemia of chronic kidney disease But phosphate is only part of the problem. The uremic environment of kidney failure also brings chronic inflammation, oxidative stress, imbalances in calcium-phosphate regulation, and accumulation of uremic toxins, all of which converge on the smooth muscle cells and push them toward their bone-building identity.15PubMed Central. Vascular Calcification in Chronic Kidney Disease: Diversity in the Vessel Wall
Diabetes drives calcification through a different but overlapping set of mechanisms. Chronically elevated blood sugar produces molecules called advanced glycation end products (AGEs), which accumulate in blood vessel walls and trigger signaling cascades that promote osteogenic transformation of smooth muscle cells. The AGE/RAGE signaling axis increases oxidative stress and upregulates bone matrix proteins through multiple intracellular pathways, contributing to the phenotypic switch that underlies calcification.16PubMed Central. The Role of AGE/RAGE Signaling in Diabetes-Mediated Vascular Calcification In people with peripheral artery disease, diabetes is particularly associated with calcification in the arteries of the lower legs, while hypertension tends to drive calcification higher up in the aortoiliac segment.17PubMed Central. The risk factors for calcification vary among the different sections of the lower extremity artery in patients with symptomatic peripheral arterial disease
Why Menopause Changes the Equation
Premenopausal women have substantially less coronary artery calcification than men of the same age, but after menopause the gap narrows rapidly. The key factor is estrogen, which normally suppresses several pro-calcification pathways. Estrogen keeps smooth muscle cells from switching to their osteogenic identity by counteracting a signaling molecule called RANKL, which drives the expression of bone-forming proteins in artery walls.18PubMed. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification It also supports the production of calcification inhibitors like MGP and dampens inflammatory signaling that would otherwise promote calcium deposition.19PubMed Central. Interplay of menopause, coronary artery calcium score and cardiovascular disease risk
When estrogen levels drop at menopause, these protective effects are lost. The result is a phenomenon sometimes called the “calcification paradox”: bone mineral density falls (leading to osteoporosis) while calcium accumulates in the arteries. The same estrogen deficiency that weakens the skeleton drives calcium into the wrong tissues, through shared disruptions in signaling pathways that regulate both bone and vascular mineralization.20PubMed Central. Postmenopausal osteoporosis and vascular calcification: The estrogen regulation network and calcification paradox Calcification in the coronary arteries and carotid arteries is generally more prevalent in men, but aortic arch calcification is actually more common in women, suggesting that sex-based differences depend on the vascular bed you are looking at.21PubMed. Association between calcification in the coronary arteries, aortic arch and carotid arteries: the Rotterdam study
What Stiff, Calcified Arteries Do to the Heart
Arteries are not passive pipes. Healthy arteries expand slightly when the heart pumps blood into them and recoil between beats, smoothing out the pulsatile flow. When arteries calcify and stiffen, they lose this elasticity. The heart now has to pump against a rigid system, which increases the workload on the left ventricle. Over time, the muscle wall of the left ventricle thickens in response, a condition called left ventricular hypertrophy. Research in elderly men with hypertension found that higher aortic calcification scores were significantly associated with increased arterial stiffness, greater left ventricular mass, and worse diastolic function, the heart’s ability to relax and fill between beats.22Journal of Hypertension. Aortic calcification is associated with arterial stiffening, left ventricular hypertrophy, and diastolic dysfunction in elderly male patients with hypertension
Stiff arteries also contribute to isolated systolic hypertension, the pattern where the top blood pressure number creeps up while the bottom number stays normal or drops. In a study of nearly 200 healthy, medication-free older adults, aortic calcification was independently associated with aortic stiffness, and people with isolated systolic hypertension had dramatically more calcification than controls.23PubMed. Aortic calcification is associated with aortic stiffness and isolated systolic hypertension in healthy individuals
Medications That Help or Hurt
Warfarin, one of the most widely prescribed blood thinners, has an unexpected dark side: it promotes vascular calcification. It works by blocking vitamin K, which is exactly what calcification inhibitor MGP needs to become activated. Without functional vitamin K, MGP cannot bind calcium ions effectively, and calcium deposits in the arteries go unchecked. Studies have confirmed that warfarin use is associated with increased systemic calcification, including in coronary and peripheral arteries.24PubMed. Warfarin and Vascular Calcification In plaque tissue, warfarin has been shown to reduce the active form of MGP while increasing the inactive form, directly linking the drug to accelerated plaque calcification and a more vulnerable plaque profile.25PLoS ONE. Vitamin K-Antagonists Accelerate Atherosclerotic Calcification and Induce a Vulnerable Plaque Phenotype This is one reason newer direct oral anticoagulants, which do not interfere with vitamin K, are increasingly favored in patients at risk for vascular calcification.
Statins present a different kind of paradox. Based on coronary CT data, high-dose statins may have minimal effect on slowing coronary artery calcification and can even modestly increase calcification scores. Yet this increase appears to reflect a shift toward dense, stable macrocalcification rather than dangerous microcalcification. The net result is that statins reduce cardiovascular events despite the paradox on imaging, likely because they shrink the lipid-rich core of plaques while promoting a more armor-like calcification pattern. Higher calcium density is inversely associated with cardiac event risk, suggesting that statin-induced calcification is part of a plaque-healing process.26PubMed Central. The Complex Mechanisms and the Potential Effects of Statins on Vascular Calcification: A Narrative Review
How Doctors Detect Calcification
The coronary artery calcium (CAC) score, obtained from a quick, low-dose CT scan, is the most widely used tool for measuring calcification. It quantifies the total amount of calcium in the coronary arteries and has proven to be a reliable marker of underlying atherosclerosis, adding meaningful predictive information beyond traditional risk factors like cholesterol and blood pressure.27PubMed Central. Risk stratification of non-contrast CT beyond the coronary calcium scan A score of zero is strongly reassuring. Higher scores indicate more extensive disease, though as discussed above, the pattern of calcification matters as much as the total amount.
The CAC score has an important limitation: it only detects macrocalcification, the large stable deposits. The dangerous microcalcifications that destabilize plaques are too small for standard CT to resolve. A newer imaging technique using a radioactive tracer called 18F-sodium fluoride (18F-NaF) with PET scanning can detect actively forming microcalcifications by binding to the surface of growing calcium crystals.28PubMed Central. 18F-Sodium Fluoride (18F-NaF) for Imaging Microcalcification Activity in the Cardiovascular System Histological validation has shown that this tracer lights up regions of microcalcification that both standard CT and even micro-CT miss entirely.29Nature Communications. Identifying active vascular microcalcification by 18F-sodium fluoride positron emission tomography This means 18F-NaF PET can potentially identify which plaques are actively progressing and most dangerous, information a standard calcium score cannot provide. The technique is still largely a research tool, but it is moving toward broader clinical use.
Emerging Therapies Targeting Calcification Directly
Most current treatments for atherosclerosis target cholesterol, blood pressure, or inflammation. Few address calcification itself. That is beginning to change. SNF472, an intravenous formulation of a compound called myo-inositol hexaphosphate, works by binding directly to the surface of forming calcium-phosphate crystals and blocking their growth. In clinical trials of dialysis patients, it significantly slowed the progression of both coronary artery and aortic valve calcification compared to placebo, and it is currently in phase 3 trials.30PubMed. SNF472: a novel therapeutic agent for vascular calcification and calciphylaxis31PubMed Central. Uremic Toxin-Driven Vascular Calcification in Chronic Kidney Disease: Molecular Pathways and Integrated Phenotypes
Other experimental strategies include boosting pyrophosphate levels through enzyme replacement, activating vitamin K2 to restore MGP function (particularly relevant for people on warfarin or those who are vitamin K deficient), and using senolytic agents that clear out aged, dysfunctional cells that contribute to calcification. Each of these approaches targets a different node in the calcification network, which underscores how multifactorial the problem is. For now, these remain in various stages of research, but they represent a genuine shift toward treating calcification as a targetable process rather than an inevitable consequence of aging.
What Gut Bacteria Have to Do With It
A surprising contributor to vascular calcification comes from the gut. Certain intestinal bacteria metabolize nutrients found in red meat, eggs, and other animal products into a compound called trimethylamine, which the liver then converts to trimethylamine-N-oxide (TMAO). Elevated TMAO levels in the blood have been linked to higher cardiovascular risk for years, but more recent work has connected TMAO specifically to vascular calcification. In laboratory and animal studies, TMAO increased the expression of bone-related proteins in smooth muscle cells and promoted their osteogenic transformation. The mechanism involves activation of the NLRP3 inflammasome and NF-κB inflammatory signaling; when researchers blocked these pathways, the TMAO-induced calcification was reduced.32PubMed. Trimethylamine-N-Oxide Promotes Vascular Calcification Through Activation of NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome and NF-κB (Nuclear Factor κB) Signals
This finding adds a dietary and microbial dimension to vascular calcification that was not appreciated even a decade ago. It also raises the possibility that modifying the gut microbiome through diet, probiotics, or other interventions could someday become part of a strategy to slow arterial calcification, though that remains speculative.
Atherosclerosis in Ancient Mummies
One of the most striking findings in cardiovascular research over the past fifteen years is that atherosclerosis is not a modern disease. The Horus study, which used CT scanning to examine Egyptian mummies, found definite or probable atherosclerosis in 20 of the 44 mummies with identifiable cardiovascular structures, spanning more than 2,000 years of ancient Egyptian history.33PubMed. Atherosclerosis in ancient Egyptian mummies: the Horus study A later expansion of the study across multiple cultures, including mummies from Peru, the American Southwest, the Aleutian Islands, and Mongolia, found atherosclerotic calcifications in about 38% of 237 mummies examined, across virtually every culture and time period represented.34European Heart Journal. Atherosclerosis in ancient mummified humans: the global HORUS study
These people lived long before processed food, sedentary office work, or cigarettes. The finding does not mean modern risk factors are irrelevant; they clearly accelerate the disease. But it does suggest that atherosclerosis has a baseline susceptibility rooted in human biology itself, likely driven by inflammation from chronic infections, smoke inhalation from cooking fires, and the fundamental interaction between immune cells and arterial walls that has been part of human physiology for millennia. Calcification, in that light, is not a byproduct of modern life. It is an ancient biological process that modern conditions have amplified.